Regeneron beats first quarter estimates on Dupixent strength

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported first-quarter results that exceeded analyst expectations, driven by strong growth in its collaboration with Sanofi on Dupixent.
Dermatology Advisor

FDA Expands Dupixent Approval to Children Aged 2 to 11 With CSU

FDA expands Dupixent approval for children aged 2 to 11 years with chronic spontaneous urticaria symptomatic despite H1 antihistamine use.
BioSpace

Garijo starts as Sanofi CEO with window to ease reliance on Dupixent

The new CEO has at least five years and a large M&A war chest to position Sanofi for life after the loss of exclusivity on ...
PharmiWeb

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Approval for children aged two to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical study programCSU is a chronic skin ...
JD Supra

First Dupixent Lawsuit Filed Over Fatal Lymphoma: What It Means for Patients and Families

The first known lawsuit has now been filed against the makers of Dupixent (dupilumab), alleging that the popular eczema and asthma drug caused or accelerated a deadly form of lymphoma. Filed in ...
Hosted on MSN

FDA clears Dupixent for young children with chronic hives

The FDA has approved Dupixent for children aged 2 to 11 with chronic spontaneous urticaria unresponsive to antihistamines, marking the first biologic for this group. The decision is based on phase 3 ...
Seeking Alpha

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® ...
Hosted on MSN

Dupixent updates, access hurdles and new hope

Dupixent continues to transform treatment for atopic dermatitis and other conditions, with new FDA approvals and updated clinical guidelines boosting its role. But patients and providers still face ...
Seeking Alpha

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and older ...
MM&M

Dupixent goes back-to-back as top Rx, OTC pharma brand in June

For the second consecutive month, Dupixent finished as the leader among the top 10 Rx and over-the-counter brands. The eczema and asthma drug from Sanofi and Regeneron had an impressions share of ...
Taiwan News

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Proportion of patients with complete response (UAS7=0).

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous ...